Israeli strikes on two Gaza homes kill 34 as new aid system remains 'chaotic'
An Israeli airstrike on a home in central Gaza killed 22 people on Thursday, including nine women and children, according to hospital officials. There was no immediate comment from the Israeli military.
Palestinians described more scenes of chaos on Thursday at an aid distribution hub in Gaza established by a new Israeli and US-backed foundation as security contractors struggled to control the crowd.
People scattered as gunfire rang out, although it was not clear who fired or if there were any casualties. Experts say a nearly three-month Israeli blockade — slightly eased in recent days — has pushed the population of roughly 2 million Palestinians to the brink of famine.
US President Donald Trump's Mideast envoy expressed optimism this week about brokering an agreement to halt the Israel-Hamas war, allow more aid into Gaza, and return more of the 58 hostages still held by Hamas, around a third of whom are alive.
Here's the latest:
Israeli strikes kill at least 34 in Gaza
An Israeli airstrike hit a house sheltering several families in Bureij, an urban refugee camp in central Gaza, killing 22 people, including nine women and children, according to officials at nearby Al-Aqsa Martyrs Hospital.
An AP journalist viewed the hospital records of the dead.
Strikes in northern Gaza late Wednesday and early Thursday hit a house, killing eight people, including two women and three children, and a car in Gaza City, killing four, local hospitals said.
There was no immediate comment from the Israeli military, which claims it only targets militants and blames civilian deaths on Hamas because the militants operate in populated areas.
Israel's war in Gaza has killed over 54,000 Palestinians, women and children, according to Gaza's Health Ministry.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
6 hours ago
- Indian Express
This word means: Ketamine
Billionaire Elon Musk engaged in extensive drug consumption as he became one of Donald Trump's closest advisers, taking ketamine so frequently it caused bladder problems and traveling with a daily supply of approximately 20 pills, according to a report by the New York Times. Musk had previously said that he was prescribed ketamine for depression, taking it about every two weeks. Ketamine is an anaesthetic that has been listed as a hallucinogen by the US Drug Enforcement Administration. It is referred to as a 'dissociative anaesthetic hallucinogen' because it creates a feeling of detachment from pain and the environment. In the US, ketamine was first used as an anaesthetic for animals in the 1960s. Around a decade later, the US Food and Drug Administration approved it for humans. The drug's use for treating depression and other mental illnesses is recent. Owing to its powerful effects, ketamine is consumed by those patients who haven't responded to traditional therapies. Ketamine is also used as a recreational drug, popularly known as K or Special K among clubgoers. Mental illness patients usually take ketamine through an IV, nasal spray or tablet once or twice a week for six to eight weeks (some might need it for longer). When it comes to recreational purposes, it is consumed by snorting a white crystalline powder. Ketamine can also be injected or smoked. In a recent report, The New York Times talked to 40 ketamine patients, many of whom said the drug was like a reset button for the brain. 'During treatment sessions, they experienced pleasant visualisations, sometimes accompanied by a sense of existing outside themselves and melding with the universe. Afterwards, their daily problems seemed less weighty,' according to the report. It also noted that ketamine garnered popularity as it affects brain receptors that traditional antidepressants do not target. 'The psychedelic-like trip, many believe, is integral to the drug's therapeutic effect,' the report said. If taken in high doses, the anaesthetic quality of ketamine becomes more pronounced. Some may find it difficult to move and may feel numb, and can experience more graphic hallucinations. 'This is sometimes called the 'k-hole' by users,' according to The Guardian. It's hard to say. Some doctors have emphasised that if taken only for medicinal purposes and in the right doses, ketamine is safe to consume and very effective in treating mental illnesses. However, many patients quoted in the NYT report said the drug can be addictive and, when taken chronically in high doses, can cause severe bladder damage. 'There are indications that abuse may also lead to cognitive impairment,' according to the report. Moreover, there has not been much research on prolonged ketamine treatment to determine if it's safe or not. There is also a lack of literature on addiction and abuse among medical users.
New Indian Express
8 hours ago
- New Indian Express
Sun Pharma's Checkpoint buy: Why it's a strategic fit in the new SPIL focus
CHENNAI: India's largest drug maker, Sun Pharmaceutical Industries, has completed its acquisition of US-based Checkpoint Therapeutics for approximately $355 million. This strategic move significantly strengthens Sun Pharma's oncology and dermatology portfolio, aligning with its focus on high-value specialty therapies. Despite the long-term strategic value, the market reaction on Friday surprised many, as Sun Pharma's share price fell by 1.46% at the close of the week's trading. This dip may have been driven by immediate concerns, including regulatory issues at a key manufacturing facility and the company's cautious financial guidance. Investors are closely monitoring developments—particularly the US FDA's observations regarding Sun Pharma's Dahej facility. The company's financial performance in the coming quarters will also be under scrutiny as stakeholders assess the potential impact on its stock trajectory. Strategic Rationale and Synergies of the Checkpoint Deal Drug industry analysts believe the Checkpoint acquisition is a major strategic gain for Sun Pharma, which has historically grown through carefully chosen, high-potential acquisitions. According to analysts at HDFC Securities, the deal aligns with Sun Pharma's capital allocation strategy to strengthen its specialty business. Checkpoint's Unloxcyt—a novel skin cancer drug—will serve as a complementary addition to its oncology portfolio. In the post-Q4 earnings call, Chairman and Managing Director Dilip Shanghvi reiterated the company's commitment to expanding its specialty business. Sun Pharma's specialty and innovative therapeutics division currently focuses on dermatology, ophthalmology, and oncology. Unloxcyt will complement existing products such as Odomzo (sonidegib) and Yonsa (abiraterone acetate)—both approved in the US—Nidlegy (awaiting approval in the EU), and the recently acquired Fibromun (in Phase III trials). Other specialty molecules in development, including Ilumya (for psoriatic arthritis), GL0034 (obesity), MM-II (osteoarthritis), SCD-044 (atopic dermatitis/psoriasis), and Fibromun (for soft tissue sarcoma/glioblastoma), offer long-term growth potential. According to analysts, the Checkpoint acquisition is strategically significant for four key reasons:
The Hindu
9 hours ago
- The Hindu
How do GLP-1 drugs work? This book answers all your questions
Dresses are shrinking. Menus are shifting. Supermarkets are changing. Ozempic, or the 'fat shot' medication, as United States President Donald Trump calls it, is transforming the way America eats, dresses and shops. Alexandra Sowa, who just released 'The Ozempic Revolution: A Doctor's Proven Plan for Success to Help You Reverse Obesity, End Yo-Yo Dieting, and Protect Yourself from Disease'(published by HarperCollins) says that as a doctor specialising in obesity, GLP-1s are the most effective tool she has to treat patients today. She adds that one in eight Americans use the medication at this point, leading to huge cultural shifts in the country. 'It has changed how people buy clothes and how they shop at the grocery store. There is a reduction in the sale of junk food. When you are on it, your tastebuds change, you want healthier food,' she says, over a Zoom call from New York, where she runs SoWell, a clinic and brand tailored to support GLP-1 users. GLP-1s are Glucagon-like peptide-1 agonist drugs that include Ozempic, Wegovy, Mounjaro and Zepbound. There is still a lot of confusion about the medication, which is why Dr. Sowa, who is a dual board-certified physician in internal and obesity medicine with more than 10 years of experience working with GLP-1, says she felt the need to write the book. 'I was one of the first doctors using this in the US, so this is the first comprehensive user guide out in the market. People have so many questions: how does it work, how you eat, how do you think, how do you move… I try to answer all that.' She adds, 'You see people on social media talking about 'Ozempic face' and 'Ozempic hands', but those are headlines wrapped around the fear people have of these medications.' She cautions that the weekly injectables, hailed as a miracle drug by actors and influencers, do not guarantee a cure. 'Medication is not an easy fix… We need to take lifestyle into account,' she says, adding 'We have to make sure we are focussing on protein. We have to strength train.' As she says in her book 'You still need to put in the work. You still have to do the work to change your underlying habits and thought patterns related to food and weight. The drug only provides a window in which making these changes is easier and more effective long-term, because the medication normalises the underlying hormonal dysfunction. GLP-1s will almost guarantee you'll lose weight, but only by using them in partnership with lifestyle changes will you maintain the loss long-term.' Also, contrary to what social media tells you, not everyone can or should take it. 'I still advocate just diet and lifestyle changes for some people,' says Dr. Sowa, adding 'What I fear is with this widespread acceptance there has been abuse. I only prescribe it for someone who has a BMI of 27. For people who have high cholesterol, insulin resistance and significant weight gain on their waistline. This is not about getting skinny.' GLP-1 medication will also evolve. 'We have a lot of new drugs in the pipeline — they are going to become tailor-made for specific needs. Maybe one for fatty liver or one that is very effective with diabetes. We are going to become better at how we make it, and with the pill version, access will become easier,' she says. While this is certainly altering the weight loss industry, she says that it does not make it any less relevant. 'I don't think gyms are going to go away — we need to embrace how people are using these places, welcoming them with open arms and no judgement. I think there is going to be less of that multi-billion industry for 'quick weight loss in 30 days', and instead people will go back to the basics of health.' ('The Ozempic Revolution'is available on and is at a listed price of ₹499)
